<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35008">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650817</url>
  </required_header>
  <id_info>
    <org_study_id>RAD1901-106</org_study_id>
    <secondary_id>2015-003555-22</secondary_id>
    <secondary_id>L54809.042.15</secondary_id>
    <nct_id>NCT02650817</nct_id>
  </id_info>
  <brief_title>A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer</brief_title>
  <official_title>A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to visualize and quantify ER-binding sites during treatment
      with RAD1901
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of RAD1901 treatment on the estrogen receptor (ER) expression and estradiol binding to the ER in lesions from patients with metastatic breast cancer (mBC)</measure>
    <time_frame>14 Days after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of FES uptake after RAD1901 treatment to clinical response</measure>
    <time_frame>Every 8 weeks for to up 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines</measure>
    <time_frame>Every 8 weeks for to up 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability assessed in terms of adverse events, serious adverse events, ECG, physical examination, vital signs, and laboratory values</measure>
    <time_frame>Up to 30 days after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of RAD1901 will be assessed at predefined intervals</measure>
    <time_frame>Every 28 days for up to 12 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>RAD1901</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD1901</intervention_name>
    <description>RAD1901, a novel selective ER degrader (SERD)</description>
    <arm_group_label>RAD1901</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Patients with histologically-proven, ER-positive, human epidermal growth factor
             receptor 2 (HER2)-negative, locally advanced, inoperative, and/or mBC

          2. Tumor progression after ≥ 6 months of at least 1 line of hormonal systemic treatment
             (SERM, SERD, or aromatase inhibitor) in the metastatic setting

          3. Measurable disease according to RECIST criteria v1.1 or clinically evaluable disease

          4. Greater than or equal to 18 years of age

          5. Patients must be post-menopausal

          6. Life expectancy &gt;3 months

        Key Exclusion Criteria:

          1. Prior anti-cancer treatment or investigational drug therapy within the following
             windows:

               1. Tamoxifen or fulvestrant therapy &lt; 42 days before 1st 18FES-PET scan

               2. Any other anti-cancer endocrine therapy &lt; 14 days before 1st dose of study drug

               3. Any chemotherapy &lt; 28 days before 1st dose of study drug

               4. Any investigational drug therapy &lt; 28 days or 3 half-lives (whichever is longer)
                  prior to the 1st dose of study drug

          2. Patients with symptomatic central nervous system (brain) metastases

          3. Patients with known endometrial disorders, including evidence of endometrial
             hyperplasia, dysfunctional uterine bleeding, or cysts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janine McDermott</last_name>
    <phone>617-551-4078</phone>
    <email>JMcDermott@radiuspharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Huyvaert</last_name>
      <phone>32(0)2 541 38 33</phone>
      <email>nathalie.huyvaert@bordet.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Neven, MD</last_name>
      <phone>32-16-34-46-29</phone>
      <email>patrick.neven@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum (VUMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catharina Willemien-Menke-van-der-Houven-van-Oordt, MD</last_name>
      <phone>+31 (0)20 44 44336</phone>
      <email>c.menke@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Catharina Willemien-Menke-van-der-Houven-van-Oordt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth GE de Vries, MD</last_name>
      <phone>+31 (0)50 3612934</phone>
      <email>e.g.e.de.vries@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Elisabeth GE de Vries, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Jager, MD</last_name>
      <phone>+31 (0)10 704 17 33</phone>
      <email>a.jager@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Agnes Jager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>January 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
